Skip to main content

Advertisement

Table 1 Baseline Clinical Characteristics of Study Patients

From: Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study

  All Patients Trimetazidine Placebo
Mean age (years) 65.4 ± 6.3 65.6 ± 5.7 65.2 ± 7
Male 24 11 13
Female 8 5 3
BMI 25.4 ± 3.2 25.7 ± 3.3 25.2 ± 3.3
Baseline glucose 164.6 ± 26.2 166.9 ± 21.9 162.2 ± 30.4
Triglycerides at baseline 238.1 ± 59.5 231.3 ± 43.7 244.9 ± 72.9
Triglycerides at randomisation 185.7 ± 46.4 180.5 ± 34 191 ± 57
Cholesterol at baseline 264.5 ± 27.8 263.3 ± 29.3 265.2 ± 27.2
Cholesterol at randomisation 198.3 ± 20.8 197.8 ± 21.9 198.8 ± 20.4
HBA1c 7.6 ± 0.8 7.7 ± 1 7.5 ± 0.6
Prior MI 18 9 9
Prior CABG 7 4 3
Prior PTCA 12 6 8
Carotid Atherosclerosis 12 7 5
Coronary atherosclerosis    
   1 vessel disease 1 0 1
   2 vessel disease 14 6 8
   3 vessel disease 16 9 7
   any vessel + graft 1 1 0
   distal disease 23 12 11
USE OF DRUGS AT RANDOMISATION    
Aspirin/ticlopidine 18 12 14
Clopidogrel 6 6 4
Anticoagulants 6 5 6
Digitalis 28 13 15
Diuretics 31 16 15
Nitrates 18 8 10
B-blockers 23 11 12
Ca-antagonists 14 9 6
ACE-I 29 14 15
ARB 4 2 2
Statins 30 14 16
Oral hypoglycaemics 25 12 13
Insulin 7 4 3
  1. Clinical features of study patients. Clinical characteristics, incidence of previous myocardial infarction or revascularization procedures in patients randomized to trimetazidine or placebo. No significant differences were detected between groups. BMI = body mass index, MI = myocardial infarction, CABG = coronary artery by-pass grafting, PC I = percutaneous coronary interventions.